Physician profile
Bijan Razi
NPI 1255365813
$583.85
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $116 · 2021: $310 · 2022: $37.12.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $283.65 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $106.29 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.10 | 2020-2021 | |
| Amgen INC. | $31.86 | 2021 | |
| Boston Scientific Corporation | $24.14 | 2021 | |
| Medtronic Vascular, INC. | $21.79 | 2020 | |
| Astellas Pharma US INC | $21.03 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $18.84 | 2019 | |
| Abbott Laboratories | $18.24 | 2021 | |
| Pfizer INC. | $15.91 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bijan Razi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.